deutetrabenazine

Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia
Hubert H Fernandez, David Stamler, Mat D Davis, Stewart A Factor, Robert A Hauser, Joohi Jimenez-Shahed, William G Ondo, L Fredrik Jarskog, Scott W Woods, Danny Bega, Mark S LeDoux, David R Shprecher, Karen E Anderson

Journal of Neurology, Neurosurgery & Psychiatry Dec 2019, 90 (12) 1317-1323; DOI: 10.1136/jnnp-2018-319918
M1 Deutetrabenazine: update on first time use of SD-809 in huntington’s disease (First-HD) and alternative for reducing chorea in huntington’s disease (ARC-HD)
Claudia Testa, on behalf of the Huntington Study Group

Journal of Neurology, Neurosurgery & Psychiatry Sep 2016, 87 (Suppl 1) A101; DOI: 10.1136/jnnp-2016-314597.286
I40 Number needed to harm (NNH) analysis of deutetrabenazine (DTB) and tetrabenazine (TBZ) from two pivotal trials: First-HD and Tetra-HD
Daniel O Claassen, Lisa De Boer, Ravi Iyer, Rajeev Ayyagari, Fan Mu, Sanjay Gandhi, Benjamin Carroll, David Stamler

Journal of Neurology, Neurosurgery & Psychiatry Sep 2016, 87 (Suppl 1) A73; DOI: 10.1136/jnnp-2016-314597.205

Main menu